


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (cancelled)

7. (currently amended) A method of synergistically enhancing the chemotherapeutic treatment of cancer selected from the group consisting of melanoma, pancreatic carcinoma, colon carcinoma and lung carcinoma expressing adenosine A₃-receptors comprising administering to a mammal, in need thereof, an effective amount of a high affinity adenosine A₃ receptor antagonist ~~either prior to or during administration of a~~ chemotherapeutic cancer agent characterized by developing P-glycoprotein (P-gp) or multi-drug resistance-associated protein (MRP) dependent multi-drug resistance (MDR), wherein the high affinity adenosine A₃ receptor antagonist has the effect of inhibiting the P-gp or MRP mediated drug-efflux thereby countering MDR, and wherein the high affinity adenosine A₃ receptor antagonist is selected from the group consisting of MRE3008F20, MRE3046F20, MRE3055F20, MRE3062F20, IL-10 and IL-11, and the chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, irinotecan, videsine, vinblastine and doxorubicin, ~~a compound of the formula:~~



wherein:

~~A is pyrazole;~~

~~R² is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;~~

~~R³ is furan;~~

~~R⁶ is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle;~~

or in each case, a pharmaceutically acceptable salt thereof.

Claims 8-10 (cancelled)

11. (currently amended) The method of claim 7 wherein the cancer is ~~selected from the group consisting of human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, lung carcinoma, histiocytic lymphoma, astrocytoma and keratinocytoma.~~

12. (currently amended) The method of claim ~~7~~ 11 wherein the cancer melanoma has multi-drug resistance that is P-glycoprotein dependent.

13. (currently amended) The method of claim 12 wherein the chemotherapeutic cancer agent is selected from the group consisting of paclitaxel and docetaxel ~~a taxane family compound.~~

14. (currently amended) The method of claim 12 wherein the chemotherapeutic cancer agent is vindesine ~~a vinca alkaloid compound.~~

Claims 15 and 31 (cancelled)

32. (currently amended) The method of claim ~~49~~ 7 wherein the cancer is selected from the group consisting of ~~human leukemia, melanoma, pancreatic carcinoma, breast carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, and~~ lung carcinoma, ~~histiocytic lymphoma, astrocytoma and keratinocytoma.~~

33. (currently amended) The method of claim 32 wherein the high affinity adenosine A₃ receptor antagonist is selected from the group consisting of MRE3008F20, ~~MRE3046F20, MRE3055F20, MRE3062F20,~~ IL-10 and IL-11.

34. (currently amended) The method of claim 33 wherein the ~~taxane family compound~~ chemotherapeutic cancer agent is selected from the group consisting of paclitaxel and docetaxel.

35. (currently amended) The method of claim 33 wherein the ~~vinca alkaloid compound~~ chemotherapeutic cancer agent is vinblastine.

36. (currently amended) The method of claim 33 wherein the ~~camptothecin compound~~
chemotherapeutic cancer agent is ~~irinotecan~~ irinotecan.

37. (currently amended) The method of claim 33 wherein the ~~antibiotic compound~~
chemotherapeutic cancer agent is doxorubicin.

Claims 38-42 (cancelled)